Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accounts Payables (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Accounts Payables for 7 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 57.26% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2025, down 57.26%, and an annual FY2025 reading of $2.0 million, down 57.26% over the prior year.
  • Accounts Payables was $2.0 million for Q4 2025 at Keros Therapeutics, down from $2.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.7 million in Q2 2022 and bottomed at $1.4 million in Q2 2021.
  • Average Accounts Payables over 5 years is $4.1 million, with a median of $4.0 million recorded in 2023.
  • The sharpest move saw Accounts Payables crashed 71.72% in 2021, then soared 458.31% in 2022.
  • Year by year, Accounts Payables stood at $3.6 million in 2021, then dropped by 8.4% to $3.3 million in 2022, then soared by 63.22% to $5.4 million in 2023, then decreased by 15.56% to $4.6 million in 2024, then tumbled by 57.26% to $2.0 million in 2025.
  • Business Quant data shows Accounts Payables for KROS at $2.0 million in Q4 2025, $2.3 million in Q3 2025, and $5.3 million in Q2 2025.